Open Innovation in Drug Development
The Express Pharma website reported that the complexities involved in commercializing any new drug has led pharma companies to adopt a more open, collaborative approach for their research and development processes. There are several advantages to introducing open innovation for the drug creation process. Open innovations and collaborations have managed
Comments Off on Open Innovation in Drug Development • Read this story »
More Articles
Corporate Hub as a Governance Structure for Coupled Open Innovation in Large Firms
The Wiley Online Library website posted a study which addresses how the open innovation concept can be applied in large corporations aiming to work with small innovative firms. More specifically, it reports an in depth qualitative study of how AstraZeneca, a global bio-pharmaceutical corporation, designed
Comments Off on Corporate Hub as a Governance Structure for Coupled Open Innovation in Large Firms • Read this story »
AstraZeneca Scientist Knighted
The PharmaLetter website reported that Mene Pangalos, one of the leaders behind AstraZeneca’s remarkable recent record of successful drug development, has been awarded a knighthood. Sir Mene’s is executive vice president of BioPharmaceuticals Research and Development at AstraZeneca. Sir Mene has
Comments Off on AstraZeneca Scientist Knighted • Read this story »
Managerial Challenges of Outbound Open Innovation
the R&D Management Journal posted a study which noted that while the research on open innovation is flourishing, less attention has so far been given to ‘outbound’ processes in comparison to ‘inbound’ and ‘coupled’ open innovation. In this paper we analyze a qualitative case study
Comments Off on Managerial Challenges of Outbound Open Innovation • Read this story »
Innovation in the Open
An article on the Chemistry World website noted a trend in open innovation: rather than drawing start-ups closer to obtain their intellectual property, some firms are shifting to a more collaborative approach. This strategy foresees collaboration agreements, or business support, and subsequent shared
Comments Off on Innovation in the Open • Read this story »
Nottingham BRC Signs for Open Innovation Platform
The Labmate website reported that leading research teams at the NIHR Nottingham Biomedical Research Centre are to collaborate over the next two years with their counterparts in the IMED Biotech Unit at global biopharmaceutical company, Astra Zeneca. Nottingham is the first NIHR Biomedical Research
Comments Off on Nottingham BRC Signs for Open Innovation Platform • Read this story »
AstraZeneca CEO Heralds New Era of Collaboration
The Cambridge Independent website reported that AstraZeneca CEO Pascal Soriot announced that the company’s advanced drug discovery robot, NiCoLA-B, will be housed in the biopharmaceutical company’s new £500million global research and development center, heralding a new era of openness and
Comments Off on AstraZeneca CEO Heralds New Era of Collaboration • Read this story »
Europe has Untapped Medical Innovation
The PharmaPhorum website noted that the ‘open innovation’ strategy is being pursued by all the big pharma companies – and now it’s simply a matter of who executes best on this approach. This is one of the boldest efforts in big pharma to create relationships with entrepreneurs, scientists and
Comments Off on Europe has Untapped Medical Innovation • Read this story »
Open Innovation: the ‘New Normal’ in Med Research?
The AstraZeneca website described AstraZeneca’s success in using open innovation. “Collaboration is essential to advancing our understanding of human diseases and accelerating the discovery and development of ground-breaking treatments that benefit patients. Such partnerships can span academic,
Comments Off on Open Innovation: the ‘New Normal’ in Med Research? • Read this story »
Open Innovation and Big Pharma
The PMLive website reported that there has been a major drive towards an open innovation model among big pharma companies, seeking to forge closer ties with small biopharma companies and academic groups in recognition that relying on in-house pharma R&D is no longer enough to remain competitive.
Comments Off on Open Innovation and Big Pharma • Read this story »